0001437749-18-020370.txt : 20181113 0001437749-18-020370.hdr.sgml : 20181113 20181113070807 ACCESSION NUMBER: 0001437749-18-020370 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20181113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InfuSystem Holdings, Inc CENTRAL INDEX KEY: 0001337013 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 203341405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35020 FILM NUMBER: 181175039 BUSINESS ADDRESS: STREET 1: 31700 RESEARCH PARK DRIVE CITY: MADISON HEIGHTS STATE: MI ZIP: 48071 BUSINESS PHONE: (248) 291-1210 MAIL ADDRESS: STREET 1: 31700 RESEARCH PARK DRIVE CITY: MADISON HEIGHTS STATE: MI ZIP: 48071 FORMER COMPANY: FORMER CONFORMED NAME: HAPC, Inc. DATE OF NAME CHANGE: 20060425 FORMER COMPANY: FORMER CONFORMED NAME: Healthcare Acquisition Partners Corp. DATE OF NAME CHANGE: 20050824 8-K 1 infu20181112_8k.htm FORM 8-K infu20181112_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2018

_________________________

InfuSystem Holdings, Inc.

(Exact name of registrant as specified in its charter)

_________________________

 

Delaware

001-35020

20-3341405

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

 

31700 Research Park Drive

Madison Heights, Michigan 48071

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (248) 291-1210

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

     Emerging growth company    ☐

 

     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Page 1 of 3

 

 

Item 2.02. Results of Operations and Financial Condition

 

On November 13, 2018, InfuSystem Holdings, Inc. issued a press release reporting its financial results for the third quarter and nine months ended September 30, 2018. A copy of the press release is furnished as an exhibit to this Form 8-K.

 

The information contained in this item 2.02, including the exhibit attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

        

99.1     Press Release of InfuSystem Holdings, Inc. dated November 13, 2018.

 

Page 2 of 3

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

INFUSYSTEM HOLDINGS, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Gregory Schulte

 

 

 

Gregory Schulte

 

 

 

Chief Financial Officer

 

 

 

Dated: November 13, 2018

 

Page 3 of 3

EX-99.1 2 ex_129517.htm EXHIBIT 99.1 ex_129517.htm

Exhibit 99.1

 

InfuSystem Holdings, Inc.
    31700 Research Park Drive
    Madison Heights, MI 48071
    248-291-1210
CONTACT: Joe Dorame, Joe Diaz & Robert Blum  
  Lytham Partners, LLC  
  602-889-9700  

 

 

InfuSystem Holdings, Inc. Reports THIRD QUARTER 2018 Financial REsults

 

Steady Growth and Near Doubling of Year-to-Date Cash Flow to $8.1 million;

Reaffirm 2018 AEBITDA Target of $14 million

 

MADISON HEIGHTS, MICHIGAN, November 13, 2018—InfuSystem Holdings, Inc. (NYSE American LLC: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today reported financial results for the third quarter ended September 30, 2018.

 

Third Quarter and Year-to-Date Highlights:

 

Cash flows provided by operating activities were $8.1 million year-to-date, up $4.0 million or 97% from the same period of 2017.

 

Net revenues for the three and nine months ended September 30, 2018 were $16.7 million and $49.6 million, respectively, a decrease of $0.9 million, or 5%, and $2.6 million, or 5%, respectively, from the same prior year periods. Absent the implementation of ASC 606, net revenues for the three and nine months ended September 30, 2018 would have been $18.1 million and $54.4 million, respectively, an increase of $0.6 million, or 3%, and $2.2 million, or 4%, respectively, from the same prior year periods.

 

Adjusted earnings before interest, taxes, depreciation and amortization (“AEBITDA”) for the three and nine months ended September 30, 2018 was $3.3 million and $10.0 million, respectively, a $0.6 million, or 15%, decrease and $1.7 million, or 20%, increase, respectively, from the same prior year periods.

 

Net loss for the three and nine months ended September 30, 2018 was $0.5 million, or $0.03 per share, and $0.8 million, or $0.04 per share, respectively, compared to a net loss of $0.1 million, or $0.01 per share, and $2.7 million, or $0.12 per share, in the same prior year periods, respectively.

 

Commenting on the third quarter, Richard DiIorio, Chief Executive Officer of InfuSystem, said, “InfuSystem continued its solid 2018 year-to-date performance during the third quarter.  We are making strong progress and gaining traction on our strategic initiatives that we believe will lead to significant oncology market share gains in 2019.  This includes the introduction during the third quarter of InfuSystem Mobile, a “first of its kind” mobile application to enhance safety and communication.  Also setting us up strong for 2019 is our continuing success in winning new business for InfuBLOCK, our highly effective alternative to opioid pain management.”

 

Page 1 of 11

 

 

“As was the case in the second quarter, the year-over-year comparisons are difficult and can obscure the progress we believe InfuSystem is making in improving its operations and future prospects. In addition to the revenue reporting changes required by ASC 606, the sharp adjustments to our business that began in 2017 and continue in 2018, have resulted in some choppy quarterly financial reports. The underlying direction, however, is very positive with evidence of this reflected in the company’s steady growth, our much stronger operating cash flow, and in our confidence that we will achieve substantially improved 2018 year-end adjusted EBITDA results.”

 

Mr. DiIorio continued, “InfuSystem’s board of directors and management team are focused on strategies that will deliver substantial long-term value creation for shareholders while ensuring superior care and service to our customers. In the recently completed third quarter, we were successful in eliminating a long-running distraction to our business plan, when we won a contested proxy fight and then used our strong cash flow and improved banking relationship to execute a significant repurchase of outstanding shares. With the company’s much improved financial condition, we have been able to both invest in future growth opportunities and execute year-to-date stock repurchases totaling $10.3 million, approximately 14% of our outstanding shares.”

 

Implementation of ASC 606:

Effective January 1, 2018, InfuSystem adopted, on a modified retrospective approach, Accounting Standards Codification Topic 606: Revenue from Contracts with Customers (“ASC 606”). The effect of this change is to remove from reported revenue, for periods beginning on the effective date, the amount the Company recorded as a provision for doubtful accounts (“Bad Debt”) during such period. The adoption on a modified retrospective approach means that the Company will not restate its financials for the periods prior to the adoption of ASC 606.

 

Page 2 of 11

 

 

The adoption of ASC 606 resulted in a reclassification of $1.5 million and $4.8 million for the three and nine months ended September 30, 2018, respectively. These amounts, which previously would have been reported as Bad Debt on the Company’s income statement, are instead reflected as reductions in reported net revenues - rentals.

 

Results for the Three and Nine Months Ended September 30, 2018

Gregory Schulte, Chief Financial Officer, said, “Our continuing success in better managing our pump fleet, improving collections from our third-party payors, and generally improving our operating efficiencies and expenses can be seen in InfuSystem’s significantly improved cash flows and our much-strengthened banking relationship.”

 

Cash flows provided by operating activities for the nine months ended September 30, 2018 were $8.1 million, a 97% increase compared with cash flows provided by operating activities for the nine months ended September 30, 2017 of $4.1 million. The Company has utilized this year-to-date increase in operating cash to increase its net investment in medical equipment and property by $2.7 million and reduce its net outflows for financing activities by $1.7 million, despite financing $1.7 million of stock repurchases through internal cash flows.

 

Net revenues for the third quarter of 2018 were $16.7 million, a $0.9 million decrease, or 5%, compared to $17.6 million for the third quarter of 2017. Absent the aforementioned implementation of ASC 606, total net revenues would have been $18.1 million, a $0.6 million increase, or 3%, compared to the same prior year period. In addition, net revenues - rentals, absent the implementation of ASC 606, would have been $15.2 million, a decrease of $0.1 million, or 1%, compared to the same prior year period and net revenues from product sales were $2.9 million, an increase of $0.6 million, or 28%, compared to the same period of 2017.

 

Net revenues for the nine months ended September 30, 2018 were $49.6 million, a $2.6 million decrease, or 5%, compared to $52.2 million for the nine months ended September 30, 2018. Absent the implementation of ASC 606, total net revenues would have been $54.4 million, a $2.2 million increase, or 4%, compared to the same prior year period. In addition, net revenues - rentals, absent the implementation of ASC 606, would have been $47.1 million, an increase of $1.8 million, or 4%, compared to the same prior year period and net revenues from product sales were $7.3 million, an increase of $0.4 million, or 5%, compared to the same period of 2017.

 

Page 3 of 11

 

 

The net loss for the three and nine months ended September 30, 2018 was $0.5 million, or $0.03 per share, and $0.8 million, or $0.04 per share, respectively, compared to a net loss of $0.1 million, or $0.01 per share, and $2.7 million, or $0.12 per share, in the same prior year periods, respectively. AEBITDA was $3.3 million and $10.0 million for the three and nine month ended September 30, 2018, respectively, a $0.6 million, or 15%, decrease and $1.7 million, or 20%, increase, respectively, compared to the same prior year periods. The quarterly net income decrease was primarily driven by increased Bad Debt and cost of revenues due to decreased margins on selective disposable supplies and increased labor servicing expenses on pump demand, decreased amortization of fully amortized intangible assets, and net increased selling, general and administrative expenses primarily due to increases in stock compensation expense, incentive bonus accrual and increased costs related to the annual shareholder meeting. These decreases to net income were partially offset by increased net revenues and decreased income tax provision.

 

The year-to-date net income increase was primarily driven by increased net revenues and decreased amortization of fully amortized intangible assets and selling and marketing expenses, and net increased selling, general and administrative expenses primarily due to increases in stock compensation expense, incentive bonus accrual, and increased costs related to the annual shareholder meeting. These increases to net income were partially offset by increased cost of revenues due to decreased margins on selective disposable supplies and increased labor servicing expenses on pump demand and decreased income tax benefit from prior year.

 

Conference Call

The Company will conduct a conference call for investors on Tuesday, November 13, 2018 at 9:00 a.m. Eastern Time to discuss third quarter results. Richard DiIorio, Chief Executive Officer, and Gregory Schulte, Chief Financial Officer, will discuss the Company’s financial performance and answer questions from the financial community. The conference call may also include a discussion of Company developments, forward-looking statements and other material information about business and financial matters. To participate in this call, please dial in toll-free (833) 366-1127 or (412) 902-6773. Additionally, a Web replay will be available on the Company’s website for 90 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10126158, through November 20, 2018.

 

Page 4 of 11

 

 

Non-GAAP Measures

This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. It is management’s intent to provide non-GAAP financial information in order to enhance readers’ understanding of its consolidated financial information as prepared in accordance with GAAP. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure and the corresponding GAAP financial measures are presented so as to not imply that more emphasis should be placed on the non-GAAP measure. The non-GAAP financial information presented may be determined or calculated differently by other companies. Additional information about non-GAAP financial measures and a reconciliation of those measures to the most directly comparable GAAP measures are included later in the appendixes attached in this release.

 

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. The Company’s stock is traded on the NYSE American LLC under the symbol INFU.

 

Page 5 of 11

 

 

Forward-Looking Statements 

The financial results in this press release reflect preliminary results, which are not final until the Company's Form 10-Q for the quarter ended September 30, 2018 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements include statements relating to future actions, business plans, objectives and prospects, future operating or financial performance, including the preliminary financial results contained in this press release. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, the potential changes in overall healthcare reimbursement, including Centers for Medicaid and Medicare Services (“CMS”) competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company’s ability to implement information technology improvements and to respond to technological changes, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and the ability to comply with Credit Facility covenants, and other risks associated with its common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2017 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. Our annual report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

 

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

 

FINANCIAL TABLES FOLLOW

 

Page 6 of 11

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   

As of

 
   

September 30,

   

December 31,

 

(in thousands, except share data)

 

2018

   

2017

 
                 
                 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 3,882     $ 3,469  

Accounts receivable, less allowance for doubtful accounts of $5,769 and $6,514 at September 30, 2018 and December 31, 2017, respectively

    10,043       11,385  

Inventories

    1,985       1,764  

Other current assets

    1,303       1,049  

Total Current assets

    17,213       17,667  

Medical equipment held for sale or rental

    2,214       1,567  

Medical equipment in rental service, net of accumulated depreciation

    21,932       23,369  

Property & equipment, net of accumulated depreciation

    1,494       1,633  

Intangible assets, net

    21,002       24,514  

Other assets

    137       131  

Total assets

  $ 63,992     $ 68,881  

LIABILITIES AND STOCKHOLDERS’ EQUITY

               

Current liabilities:

               

Accounts payable

  $ 7,059     $ 5,516  

Capital lease liability, current

    101       505  

Current portion of long-term debt

    4,775       3,039  

Other current liabilities

    2,727       3,414  

Total current liabilities

    14,662       12,474  

Long-term debt, net of current portion

    28,661       25,352  

Capital lease liability, long-term

    -       33  

Deferred income taxes

    62       62  

Other long-term liabilities

    -       7  

Total liabilities

  $ 43,385     $ 37,928  

Stockholders’ equity:

               

Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued

    -       -  

Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,050,984 and 19,565,091, respectively, as of September 30, 2018 and 22,978,398 and 22,780,738, respectively, as of December 31, 2017

    2       2  

Additional paid-in capital

    83,058       92,584  

Retained deficit

    (62,453 )     (61,633 )

Total Stockholders’ equity

    20,607       30,953  

Total liabilities and stockholders’ equity

  $ 63,992     $ 68,881  

 

Page 7 of 11

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

Three Months Ended

   

Nine Months Ended

 

(in thousands, except share and per share data)

 

September 30

   

September 30

 
   

2018

   

2017

   

2018

   

2017

 

Net revenues:

                               

Rentals

  $ 13,773     $ 15,322     $ 42,246     $ 45,228  

Product Sales

    2,904       2,266       7,329       6,956  

Net revenues

    16,677       17,588       49,575       52,184  
                                 

Cost of revenues:

                               

Cost of revenues — Product, service and supply costs

    4,896       4,452       14,180       13,612  

Cost of revenues — Pump depreciation and disposals

    2,233       2,095       6,221       6,541  
                                 

Gross profit

    9,548       11,041       29,174       32,031  
                                 

Selling, general and administrative expenses:

                               

Provision for doubtful accounts

    -       1,274       -       4,456  

Amortization of intangibles

    1,160       1,384       3,512       4,182  

Selling and marketing

    2,323       2,262       6,950       7,443  

General and administrative

    6,160       5,561       18,423       18,451  
                                 

Total selling, general and administrative

    9,643       10,481       28,885       34,532  
                                 

Operating (loss) income

    (95 )     560       289       (2,501 )

Other expense:

                               

Interest expense

    (370 )     (354 )     (981 )     (1,015 )

Other expense

    (9 )     (8 )     (19 )     (111 )

(Loss) income before income taxes

    (474 )     198       (711 )     (3,627 )

(Provision for) benefit from income taxes

    (45 )     (327 )     (109 )     914  

Net loss

  $ (519 )   $ (129 )   $ (820 )   $ (2,713 )
                                 

Net loss per share:

                               

Basic and diluted

  $ (0.03 )   $ (0.01 )   $ (0.04 )   $ (0.12 )

Weighted average shares outstanding:

                               

Basic and diluted

    20,672,688       22,755,976       22,043,213       22,725,806  

 

 

Page 8 of 11

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   

Nine Months Ended

 
   

September 30

 

(in thousands)

 

2018

   

2017

 

NET CASH PROVIDED BY OPERATING ACTIVITIES

  $ 8,095     $ 4,102  
                 

INVESTING ACTIVITIES

               

Purchase of medical equipment and property

    (4,962 )     (2,829 )

Proceeds from sale of medical equipment and property

    2,900       3,518  

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

    (2,062 )     689  
                 

FINANCING ACTIVITIES

               

Principal payments on revolving credit facility, term loans and capital lease obligations

    (5,048 )     (35,769 )

Cash proceeds from credit facility

    9,660       28,317  

Debt issuance costs

    (27 )     (38 )

Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans

    (5 )     (27 )

Common stock repurchased as part of Repurchase Program

    (10,291 )     -  

Cash proceeds from stock plans

    91       131  

NET CASH USED IN FINANCING ACTIVITIES

    (5,620 )     (7,386 )
                 

Net change in cash and cash equivalents

    413       (2,595 )

Cash and cash equivalents, beginning of period

    3,469       3,398  

Cash and cash equivalents, end of period

  $ 3,882     $ 803  

 

Page 9 of 11

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(UNAUDITED)

 

NET LOSS TO ADJUSTED EBITDA:

                               
   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 

(in thousands)

 

2018

   

2017

   

2018

   

2017

 
                                 

GAAP net loss

  $ (519 )   $ (129 )   $ (820 )   $ (2,713 )

Adjustments:

                               

Interest expense

    370       354       981       1,015  

Income tax expense (benefit)

    45       327       109       (914 )

Depreciation

    1,626       1,766       4,879       5,166  

Amortization

    1,160       1,384       3,512       4,182  
                                 

Non-GAAP EBITDA

  $ 2,682     $ 3,702     $ 8,661     $ 6,736  
                                 

Stock related costs

    288       132       679       450  

Restatement Costs

    -       -       -       28  

Early termination fees for capital leases

    -       (10 )     -       292  

Shareholder costs

    87       -       234       200  

Strategic alternatives and other costs

    157       -       197       -  

Exited facility costs

    -       -       44       -  

Management reorganization/transition costs

    72       42       209       661  

Non-GAAP Adjusted EBITDA

  $ 3,286     $ 3,866     $ 10,024     $ 8,367  
                                 

GAAP Net Revenues

  $ 16,677     $ 17,588     $ 49,575     $ 52,184  

Adjustments:

                               

Bad Debt expense

    1,467       -       4,804       -  

Non-GAAP Adjusted Net Revenues

  $ 18,144     $ 17,588     $ 54,379     $ 52,184  

GAAP Gross Profit

    9,548       11,041       29,174       32,031  

Non-GAAP Adjusted EBITDA Margin

    18.1 %     22.0 %     18.4 %     16.0 %

 

Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of Non-GAAP Adjusted Net Revenues.

 

Page 10 of 11

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(UNAUDITED)

 

NET DEBT

                       
   

September 30,

   

December 31,

   

September 30,

 

(in thousands)

 

2018

   

2017

   

2017

 
                         

Current Liabilities:

                       

Capital lease liability

  $ 101     $ 505     $ 584  

Current portion of Long-term debt

    4,775       3,039       2,849  

Total Current Liabilities

    4,876       3,544       3,433  
                         

Long-Term Liabilities:

                       

Capital lease liability

    -       33       101  

Long-term debt

    28,661       25,352       26,535  

Total Long-term Liabilities

    28,661       25,385       26,636  

Total Current and Long-Term Liabilities - GAAP Debt

    33,537       28,929       30,069  

Adjustments:

                       

Less: Cash and cash equivalents

    (3,882 )     (3,469 )     (803 )
                         

Non-GAAP Total - Net Debt

  $ 29,655     $ 25,460     $ 29,266  

 

Page 11 of 11

GRAPHIC 3 infu.jpg begin 644 infu.jpg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end